drugset
drugset / Trial / NCT04529954

Anti-Epilepsy Medication Valproate Administered Via ICV Route and Catheters and Pumps for CSF Infusion

NCT04529954 ↗

Phase 1/2 Terminated 20 enrolled Cerebral Therapeutics LLC
NaSingle-groupOpen-labelTreatment

Summary

This is a non-randomized open-label extension study for subjects having completed protocol DA071976 or CLN100P.01.

Timeline

Start
2021-01-01
Primary completion
2024-03-01
Completion
2024-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Valproic Acid Small molecule — Other

Indications

focal epilepsy